Literature DB >> 8370368

Potassium channel activators in vasospastic angina.

J M Lablanche1, C Bauters, E P McFadden, P Quandalle, M E Bertrand.   

Abstract

Activation of potassium channels induces relaxation of vascular smooth muscle, and experimental studies have demonstrated that potassium channel activators have potent coronary vasodilator properties. In humans, nicorandil, a potassium channel blocker, causes vasodilatation not only in angiographically normal segments but also at sites of dynamic coronary stenosis, where coronary spasm has been provoked by methylergometrine as well as at sites of spontaneous spasm. The efficacy of nicorandil in relieving ergometrine-induced spasm is comparable to that of nifedipine. Oral administration of nicorandil significantly reduces the frequency of anginal episodes in patients with vasospastic angina, and either as monotherapy, or in conjunction with other agents is a novel therapeutic option in patients with vasospastic angina.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370368     DOI: 10.1093/eurheartj/14.suppl_b.22

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Methylergometrine-induced myocardial ischemia in a previously asymptomatic premenopausal woman.

Authors:  C Oneglia; A Marchetti; C Rusconi
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 2.  Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.

Authors:  A H Gomma; H J Purcell; K M Fox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.